EGFR and neoplasm: Preliminary results from a phase II clinical trial (NCT04036682) evaluating TAS6417 in a cohort of 37 NSCLC patients with EGFR Ex20ins previously treated with platinum-based therapy showed an acceptable safety profile and encouraging anti-tumour activity [84].